April 2010
Volume 51, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2010
Twenty-Four Hour Efficacy With the Dorzolamide/Timolol Fixed Combination Compared With the Brimonidine/Timolol Fixed Combination in Primary Open-Angle Glaucoma
Author Affiliations & Notes
  • A. G. Konstas
    1st University Dept of Ophthalmology, AHEPA Hospital, Thessaloniki, Greece
  • L. Quaranta
    Glaucoma Unit, University of Brescia, Brescia, Italy
  • D. B. Yan
    Ophthalmology Dept, University of Toronto, Toronto, Ontario, Canada
  • D. Mikropoulos
    1st University Dept of Ophthalmology, AHEPA Hospital, Thessaloniki, Greece
  • A.-B. Haidich
    Department of Hygiene, Aristotle University of Thessaloniki, Thessaloniki, Greece
  • I. Riva
    Glaucoma Unit, University of Brescia, Brescia, Italy
  • N. Gill
    Ophthalmology Dept, University of Toronto, Toronto, Ontario, Canada
  • Footnotes
    Commercial Relationships  A.G. Konstas, Alcon, Allergan, Merck, Pfizer, C; Alcon, Allergan, Merck, Pfizer, R; L. Quaranta, Alcon, Merck, R; D.B. Yan, Alcon, Allergan, Merck, R; D. Mikropoulos, Alcon, Allergan, R; A.-B. Haidich, None; I. Riva, Allergan, MSD, R; N. Gill, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 173. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      A. G. Konstas, L. Quaranta, D. B. Yan, D. Mikropoulos, A.-B. Haidich, I. Riva, N. Gill; Twenty-Four Hour Efficacy With the Dorzolamide/Timolol Fixed Combination Compared With the Brimonidine/Timolol Fixed Combination in Primary Open-Angle Glaucoma. Invest. Ophthalmol. Vis. Sci. 2010;51(13):173.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To compare the 24-hour intraocular pressure (IOP) efficacy of the dorzolamide/timolol fixed combination (DTFC) and the brimonidine/timolol fixed combination (BTFC) in primary open-angle glaucoma (POAG).

Methods: : One eye of 77 POAG patients was included in this prospective, observer-masked, crossover comparison. Following a timolol run-in period for 2 months, all patients underwent a timolol-treated daytime IOP curve with 3 separate IOP measurements performed at 10:00, 12:00 and 14:00. Patients with a mean daytime IOP greater than 18 mm Hg and at least a 20% IOP reduction on timolol were randomized to 2 months of therapy with either DTFC, or BTFC and then were switched to the opposite therapy. This 24-hour IOP study had at least 85% power to identify a 1.0 mm Hg difference between mean 24-hour IOP values assuming a standard deviation of 2.5 mm Hg between treatments.

Results: : Sixty POAG patients completed the study. The mean 24-hour IOP was significantly reduced with both fixed combinations compared with the mean daytime IOP in the timolol run-in period (P<0.001). When the two fixed combination treatments were compared directly the DTFC demonstrated a lower absolute IOP level for the 24-hour curve compared to the BTFC (mean difference: -0.7 mm Hg, 95 % confidence interval [CI]: -1.0, -0.3, P<0.001). At 2 individual time points DTFC significantly reduced IOP more than BTFC: at 18:00 (-1.0 mm Hg, 95% CI [-1.6,-0.5], p=0.001) and at 02:00 (-0.9 mm Hg, 95% CI[-1.4,-0.5], p=0.001). No significant difference existed for the other time points.

Conclusions: : Both fixed combinations significantly reduce 24-hour IOP in POAG. DTFC provided significantly better 24-hour efficacy.

Clinical Trial: : www.clinicaltrials.gov NCT00972257

Keywords: clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×